^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Capillary permeability modulator

    Related drugs:
    13d
    Low-Dose Danazol for the Treatment of Telomere Related Diseases (clinicaltrials.gov)
    P2, N=18, Active, not recruiting, National Heart, Lung, and Blood Institute (NHLBI) | Recruiting --> Active, not recruiting | N=40 --> 18
    Enrollment closed • Enrollment change
    |
    TERT (Telomerase Reverse Transcriptase) • DKC1 (Dyskerin Pseudouridine Synthase 1)
    15d
    BOLSTER: A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P2, N=66, Terminated, Lisata Therapeutics, Inc. | Trial completion date: Mar 2030 --> Apr 2026 | Active, not recruiting --> Terminated; The study was halted prematurely to allow analysis of the results.
    Trial completion date • Trial termination
    |
    cisplatin • Imfinzi (durvalumab) • gemcitabine • 5-fluorouracil • oxaliplatin • leucovorin calcium • certepetide (LSTA1)
    26d
    Low-Dose Danazol for the Treatment of Telomere Related Diseases (clinicaltrials.gov)
    P2, N=40, Recruiting, National Heart, Lung, and Blood Institute (NHLBI) | Trial primary completion date: Apr 2026 --> Apr 2027
    Trial primary completion date
    |
    TERT (Telomerase Reverse Transcriptase) • DKC1 (Dyskerin Pseudouridine Synthase 1)
    1year
    BOLSTER: A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P2, N=67, Active, not recruiting, Lisata Therapeutics, Inc. | Trial completion date: Mar 2026 --> Mar 2030 | Trial primary completion date: Apr 2025 --> Apr 2026
    Trial completion date • Trial primary completion date
    |
    cisplatin • Imfinzi (durvalumab) • gemcitabine • 5-fluorouracil • oxaliplatin • leucovorin calcium • certepetide (LSTA1)
    1year
    FORTIFIDE: Certepetide Phase 1b/2a Continuous Infusion Trial in mPDAC (clinicaltrials.gov)
    P1/2, N=0, Withdrawn, Lisata Therapeutics, Inc. | Trial completion date: Apr 2025 --> Jan 2040 | Initiation date: Jan 2025 --> Jan 2030 | Trial primary completion date: Apr 2025 --> Jan 2035
    Trial completion date • Trial initiation date • Trial primary completion date
    |
    gemcitabine • albumin-bound paclitaxel • certepetide (LSTA1)
    1year
    FORTIFIDE: Certepetide Phase 1b/2a Continuous Infusion Trial in mPDAC (clinicaltrials.gov)
    P1/2, N=0, Withdrawn, Lisata Therapeutics, Inc. | N=30 --> 0 | Trial completion date: Sep 2027 --> Apr 2025 | Not yet recruiting --> Withdrawn | Trial primary completion date: Sep 2027 --> Apr 2025
    Enrollment change • Trial completion date • Trial withdrawal • Trial primary completion date
    |
    gemcitabine • albumin-bound paclitaxel • certepetide (LSTA1)
    1year
    BOLSTER: A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P2, N=67, Active, not recruiting, Lisata Therapeutics, Inc. | Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2026 --> Apr 2025
    Enrollment closed • Trial primary completion date
    |
    cisplatin • Imfinzi (durvalumab) • gemcitabine • 5-fluorouracil • oxaliplatin • leucovorin calcium • certepetide (LSTA1)
    over1year
    CENDIFOX: CEND-1 in Combination with Neoadjuvant FOLFIRINOX with or Without Panitumumab (clinicaltrials.gov)
    P1/2, N=50, Active, not recruiting, Anup Kasi | Recruiting --> Active, not recruiting | Phase classification: P1b/2a --> P1/2 | Trial completion date: Sep 2025 --> Sep 2026 | Trial primary completion date: Sep 2023 --> Sep 2025
    Enrollment closed • Phase classification • Trial completion date • Trial primary completion date • Combination therapy
    |
    BRAF (B-raf proto-oncogene)
    |
    5-fluorouracil • Vectibix (panitumumab) • oxaliplatin • irinotecan • leucovorin calcium • certepetide (LSTA1)
    over1year
    BOLSTER: A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P2, N=80, Recruiting, Lisata Therapeutics, Inc. | Trial completion date: Dec 2025 --> Mar 2026 | Trial primary completion date: Dec 2025 --> Mar 2026
    Trial completion date • Trial primary completion date • Metastases
    |
    cisplatin • Imfinzi (durvalumab) • gemcitabine • 5-fluorouracil • oxaliplatin • leucovorin calcium • certepetide (LSTA1)
    over1year
    FORTIFIDE: LSTA1 Phase 1b/2a Continuous Infusion Trial in mPDAC (clinicaltrials.gov)
    P1/2, N=30, Not yet recruiting, Lisata Therapeutics, Inc. | Trial completion date: Jun 2027 --> Sep 2027 | Initiation date: Dec 2024 --> Mar 2025 | Trial primary completion date: Jun 2027 --> Sep 2027
    Trial completion date • Trial initiation date • Trial primary completion date • Metastases
    |
    gemcitabine • 5-fluorouracil • albumin-bound paclitaxel • oxaliplatin • irinotecan • leucovorin calcium • certepetide (LSTA1)
    over1year
    FORTIFIDE: LSTA1 Phase 1b/2a Continuous Infusion Trial in mPDAC (clinicaltrials.gov)
    P1/2, N=30, Recruiting, Lisata Therapeutics, Inc. | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    gemcitabine • 5-fluorouracil • albumin-bound paclitaxel • oxaliplatin • irinotecan • leucovorin calcium • certepetide (LSTA1)
    over1year
    FORTIFIDE: LSTA1 Phase 1b/2a Continuous Infusion Trial in MPDAC (clinicaltrials.gov)
    P1/2, N=30, Not yet recruiting, Lisata Therapeutics, Inc.
    New P1/2 trial • Metastases
    |
    gemcitabine • 5-fluorouracil • albumin-bound paclitaxel • oxaliplatin • irinotecan • leucovorin calcium • certepetide (LSTA1)